R&D | Cutting-edge science and innovative research

R&D

Why drug delivery is biotech’s overlooked challenge – and it...

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

News

SanegeneBio raises $110m for RNAi, plus other financings

Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

News

Agreement reached on EU's new pharma legislation

Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc's global status.

News

Lilly's obesity triple pulls off 29% weight loss in trial

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

News

AC Immune's chief executive Dr Andrea Pfeifer

AC Immune says Parkinson's drug slows progression

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

News

Agreement reached on EU's new pharma legislation

Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc's global status.

News

Lilly's obesity triple pulls off 29% weight loss in trial

Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide.

News

AC Immune says Parkinson's drug slows progression

AC Immune's active immunotherapy study backs up the alpha-synuclein hypothesis in Parkinson's disease, after disappointments in earlier trials.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

News

SanegeneBio raises $110m for RNAi, plus other financings

Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

News

Agreement reached on EU's new pharma legislation

Agreement has been reached on the reform of EU pharma legislation, but industry thinks it does not go far enough to restore the bloc's global status.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

Why drug delivery is biotech’s overlooked challenge – and it...

Delivery innovations don’t just improve outcomes – they reshape the entire therapy ecosystem.

R&D

The case for engagement in medical training: Why interactive...

Trainees need to be maximally empowered to connect the dots before they enter hospitals or labs.

R&D

pharmaphorum podcast Episode 227, Punit Dhillon, Skye Bioscience

On CB1s as an alternative to GLP-1s, with Punit Dhillon

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

Deep Dive

R&D

R&D Contraceptive pills condoms and intrauterine device

Research and Development

R&D

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research.

R&D

Breaking through financial barriers to clinical trials: How ...

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

Podcasts

R&D

On CB1s as an alternative to GLP-1s, with Punit Dhillon

In a new pharmaphorum podcast, Punit Dhillon, CEO of Skye Bioscience, discusses CB1 inhibitor antibodies in the obesity space.

R&D

pharmaphorum podcast Episode 225, Simon Kohl, Latent Labs

Towards a democratic era of medicine, with Simon Kohl

In a new episode, Simon Kohl discusses Latent Labs’ emergence from stealth, as well as protein design and drug discovery acceleration in more detail.

R&D

pharmaphorum podcast Episode 224, Sigma Mostafa, KBI Biopharma

CDMOs: Their crucial role and how to select one, with Sigma ...

Sigma Mostafa, CSO at KBI BioPharma, discusses the role of CDMOs and the important factors companies should consider when selecting one.

Video

R&D

Sponsored

Thermo Fisher Scientific on the value of an integrated appro...

In a new sponsored video, Thermo Fisher Scientific’s Alberto Fernández discusses the company's Accelerator Drug Development solution.

R&D

ESMO25: On partnerships between pharma and diagnostic develo...

Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific discusses CDx.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

White Papers

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.

R&D